Show simple item record

dc.contributor.authorAhmed, A
dc.contributor.authorFelmlee, Daniel
dc.date.accessioned2018-07-30T12:56:15Z
dc.date.available2018-07-30T12:56:15Z
dc.date.issued2015-12-18
dc.identifier.issn1999-4915
dc.identifier.issn1999-4915
dc.identifier.urihttp://hdl.handle.net/10026.1/11963
dc.description.abstract

There has been a remarkable transformation in the treatment of chronic hepatitis C in recent years with the development of direct acting antiviral agents targeting virus encoded proteins important for viral replication including NS3/4A, NS5A and NS5B. These agents have shown high sustained viral response (SVR) rates of more than 90% in phase 2 and phase 3 clinical trials; however, this is slightly lower in real-life cohorts. Hepatitis C virus resistant variants are seen in most patients who do not achieve SVR due to selection and outgrowth of resistant hepatitis C virus variants within a given host. These resistance associated mutations depend on the class of direct-acting antiviral drugs used and also vary between hepatitis C virus genotypes and subtypes. The understanding of these mutations has a clear clinical implication in terms of choice and combination of drugs used. In this review, we describe mechanism of action of currently available drugs and summarize clinically relevant resistance data.

dc.format.extent6716-6729
dc.format.mediumElectronic
dc.languageen
dc.language.isoen
dc.publisherMDPI
dc.subjectresistance
dc.subjecthepatitis C
dc.subjectdirect acting antivirals
dc.subjectbreakthrough variants
dc.titleMechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
dc.typejournal-article
dc.typeJournal Article
dc.typeReview
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000367536700042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue12
plymouth.volume7
plymouth.publication-statusPublished online
plymouth.journalViruses
dc.identifier.doi10.3390/v7122968
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeSwitzerland
dcterms.dateAccepted2015-12-08
dc.identifier.eissn1999-4915
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.3390/v7122968
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2015-12-18
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV